Adaptive Biotechnologies

History

Year	Detail
2009	Harlan and his brother founded Adaptive TCR.
2010	The company launched its first research product, immunoSEQ, which helps to profile and monitor the adaptive immune response.
2012	The company shifted its headquarters to Seattle, U.S.
2015	The company develops new technology to map T cells to the antigens they target, which helps in novel diagnostic tests.
2017	The company partners with Microsoft to combine their AI and ML capabilities to Adaptive's platform and scale the
2019	The company partners with Genentech to develop shared and personalized T cell-based therapies for cancer patients.
2019	The company goes public on the Nasdaq.
2020	The company, in partnership with Microsoft, shares its data for free with researchers around the world to help combat the COVID-19 virus.
	The company launched immunoSEQ T-MAP COVID, a tool for researchers that measure T-cell response to vaccines.
	The company launched T-Detect COVID, a diagnostic tool for patients that uses T cells as a market to detect recent and past infections of COVID-19.
2008	The company acquired Tusonix, Inc. to expand its product range into EMI/RFI filter components.
2012	The company acquired D&R Technology to expand its product range into the automotive sensor product platform.